Palvella Therapeutics (PVLA) Capital Expenditures (2016 - 2023)
Historic Capital Expenditures for Palvella Therapeutics (PVLA) over the last 10 years, with Q4 2023 value amounting to -$13000.0.
- Palvella Therapeutics' Capital Expenditures fell 1818.18% to -$13000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$13000.0, marking a year-over-year decrease of 10751.45%. This contributed to the annual value of $171000.0 for FY2023, which is 8357.35% down from last year.
- As of Q4 2023, Palvella Therapeutics' Capital Expenditures stood at -$13000.0, which was down 1818.18% from $69000.0 recorded in Q3 2023.
- Palvella Therapeutics' Capital Expenditures' 5-year high stood at $1.9 million during Q1 2020, with a 5-year trough of -$840000.0 in Q3 2020.
- In the last 5 years, Palvella Therapeutics' Capital Expenditures had a median value of $230500.0 in 2019 and averaged $367450.0.
- Over the last 5 years, Palvella Therapeutics' Capital Expenditures had its largest YoY gain of 149256.2% in 2020, and its largest YoY loss of 46206.9% in 2020.
- Palvella Therapeutics' Capital Expenditures (Quarter) stood at $1.2 million in 2019, then crashed by 50.85% to $578000.0 in 2020, then tumbled by 40.83% to $342000.0 in 2021, then crashed by 103.22% to -$11000.0 in 2022, then dropped by 18.18% to -$13000.0 in 2023.
- Its Capital Expenditures was -$13000.0 in Q4 2023, compared to $69000.0 in Q3 2023 and $67000.0 in Q2 2023.